The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis

Blood

Volumn 125, Issue 7, 2015, Pages 1159-1169

  Stockklausner, Clemens ^a   Klotter, Anne Christine ^a   Dickemann, Nicole ^a   Kuhlee, Isabelle N ^a   Duffert, Christin M ^a   Kerber, Carolin ^a   Gehring, Niels H ^a,b   Kulozik, Andreas E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4,5,6,7 TETRAHYDROISOXAZOLO[4,5 C]PYRIDIN 3 OL; CELL RECEPTOR; CYTOKINE; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; LEUCINE; MPL PROTEIN, HUMAN; PROLINE;

ARTICLE; BLOOD LEVEL; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE MUTATION; GLYCOSYLATION; HOMEOSTASIS; HUMAN; HUMAN CELL; MUTANT; NEGATIVE FEEDBACK; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA; THROMBOCYTOPENIA; ADULT; AMINO ACID SUBSTITUTION; CASE REPORT; CELL CULTURE; CHILD; FAMILY; FEMALE; GENETICS; HELA CELL LINE; MALE; METABOLISM; MISSENSE MUTATION; PEDIGREE; PHYSIOLOGY; PRESCHOOL CHILD; THROMBOCYTOSIS; YOUNG ADULT;

ADULT; AMINO ACID SUBSTITUTION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FAMILY; FEMALE; HELA CELLS; HOMEOSTASIS; HUMANS; LEUCINE; MALE; MUTATION, MISSENSE; PEDIGREE; PROLINE; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOPOIETIN; YOUNG ADULT;

EID: 84923269312     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-587170     Document Type: Article

References (56)

1. Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci. 2002; 17:6-10.
2. Hitchcock IS, Kaushansky K. Thrombopoietin from beginning to end. Br J Haematol. 2014; 165(2):259-268.
3. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008;111(3):981-986.
4. Ballmaier M, Germeshausen M, Schulze H, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97(1):139-146.
5. Stockklausner C, Gehring N, Echner N, Mulla NAA, Kulozik AE. Autosomal recessive hereditary thrombocytosis: functional analysis of a novel C-Mpl mutation resulting in an unsual mode of constitutive receptor activation [abstract]. ASH Annual Meeting Abstracts. 2008;112(11). Abstract 890.
6. Kondo T, Okabe M, Sanada M, et al. Familial essential thrombocythemia associated with onebase deletion in the 59-untranslated region of the thrombopoietin gene. Blood. 1998;92(4): 1091-1096.
7. Ghilardi N, Wiestner A, Kikuchi M, Ohsaka A, Skoda RC. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol. 1999;107(2):310-316.
8. Ghilardi N, Skoda RC. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood. 1999;94(4):1480-1482.
9. El-Harith El- HA, Roesl C, Ballmaier M, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol. 2009;144(2):185-194.
10. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998;18(1):49-52.
11. Zhang B, Ng D, Jones C, et al. A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. Blood. 2011; 118(26):6988-6990.
12. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-4200.
13. Tiedt R, Coers J, Ziegler S, et al. Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood. 2009; 113(8):1768-1777.
14. Lannutti BJ, Epp A, Roy J, Chen J, Josephson NC. Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood. 2009;113(8):1778-1785.
15. Constantinescu SN. Mpl and thrombocytosis: levels matter. Blood. 2009;113(8):1617-1618.
16. Liu K, Martini M, Rocca B, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009;94(10): 1368-1374.
17. Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007;25(9): 1048-1053.
18. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci USA. 2004;101(31): 11444-11447.
19. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108(10):3472-3476.
20. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
21. Teofili L, Giona F, Torti L, et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica. 2010;95(1):65-70.
22. He X, Chen Z, Jiang Y, Qiu X, Zhao X. Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases. J Hematol Oncol. 2013;6:11.
23. Teofili L, Giona F, Martini M, et al. Thrombopoietin receptor activation, thrombopoietin mimetic drugs, and hereditary thrombocytosis: remarks on bone marrow fibrosis. J Clin Oncol. 2010;28(19): e317-e318.
24. Defour JP, Itaya M, Gryshkova V, et al. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc Natl Acad Sci USA. 2013;110(7):2540-2545.
25. Germeshausen M, Ballmaier M, Welte K. MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat. 2006;27(3):296.
26. Fox NE, Chen R, Hitchcock I, Keates-Baleeiro J, Frangoul H, Geddis AE. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature. Exp Hematol. 2009;37(4):495-503.
27. Rose MJ, Nicol KK, Skeens MA, Gross TG, Kerlin BA. Congenital amegakaryocytic thrombocytopenia: the diagnostic importance of combining pathology with molecular genetics. Pediatr Blood Cancer. 2008;50(6):1263-1265.
28. van den Oudenrijn S, Bruin M, Folman CC, et al. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol. 2000;110(2): 441-448.
29. Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci USA. 2004;101(7):1816-1821.
30. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J. 1995;14(22): 5569-5578.
31. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood. 1999;94(1):365-367.
32. Abdel-Azim H, Zhu Y, Hollis R, et al. Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl. Blood. 2008;111(8):4064-4074.
33. Ding J, Komatsu H, Iida S, et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009;114(15): 3325-3328.
34. Otto KG, Broudy VC, Lin NL, et al. Membrane localization is not required for Mpl function in normal hematopoietic cells. Blood. 2001;98(7): 2077-2083.
35. Matthews EE, Thévenin D, Rogers JM, et al. Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J. 2011;25(7): 2234-2244.
36. Marty C, Chaligné R, Lacout C, Constantinescu SN, Vainchenker W, Villeval JL. Ligandindependent thrombopoietin mutant receptor requires cell surface localization for endogenous activity. J Biol Chem. 2009;284(18):11781-11791.
37. Staerk J, Defour JP, Pecquet C, et al. Orientationspecific signalling by thrombopoietin receptor dimers. EMBO J. 2011;30(21):4398-4413.
38. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembranecytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864-1871.
39. Stockklausner C, Breit S, Neu-Yilik G, et al. The uORF-containing thrombopoietin mRNA escapes nonsense-mediated decay (NMD). Nucleic Acids Res. 2006;34(8):2355-2363.
40. Sangkhae V, Saur SJ, Kaushansky A, Kaushansky K, Hitchcock IS. Phosphorylated c-Mpl tyrosine 591 regulates thrombopoietininduced signaling. Exp Hematol. 2014;42(6): 477-86.e4.
41. Moliterno AR, Spivak JL. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood. 1999;94(8): 2555-2561.
42. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999; 283(5404):987-990.
43. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science. 1999;283(5404): 990-993.
44. Gent J, van Kerkhof P, Roza M, Bu G, Strous GJ. Ligand-independent growth hormone receptordimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc Natl Acad Sci USA. 2002; 99(15):9858-9863.
45. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009;60:193-206.
46. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11):4607-4616.
47. Fox NE, Lim J, Chen R, Geddis AE. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents. Exp Hematol. 2010;38(5):384-391.
48. Orita T, Tsunoda H, Yabuta N, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood. 2005;105(2):562-566.
49. Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96(4):607-611.
50. Chen X, Qi X, Tan Y, et al. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms. Blood Cells Mol Dis. 2011;47(1): 67-71.
51. Farruggia P, D'Angelo P, La Rosa M, et al. MPL W515L mutation in pediatric essential thrombocythemia. Pediatr Blood Cancer. 2013; 60(8):E52-E54.
52. Percy MJ, Rumi E. Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis. Am J Hematol. 2009;84(1): 46-54.
53. Stockklausner C, Echner N, Klotter AC, Hegenbart U, Dreger P, Kulozik AE. Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects. Ann Hematol. 2012;91(7):1129-1133.
54. Posthuma HL, Skoda RC, Jacob FA, van der Maas AP, Valk PJ, Posthuma EF. Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis. Blood. 2010;116(17):3375-3376.
55. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.
56. Rumi E, Pietra D, Ferretti V, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-1551.